NARCAN Drug Patent Profile

When do Narcan patents expire, and what generic alternatives are available?

Narcan is a drug marketed by Adapt, Bristol Myers Squibb, and Emergent. and is included in five NDAs.

The generic ingredient in NARCAN is naloxone hydrochloride. There are twelve drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Narcan

A generic version of NARCAN was approved as naloxone hydrochloride by HOSPIRA on September 24^th, 1986.

Summary for NARCAN

US Patents:	0
Applicants:	3
NDAs:	5
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	23
Patent Applications:	4,820
Drug Prices:	Drug price information for NARCAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NARCAN
What excipients (inactive ingredients) are in NARCAN?	NARCAN excipients list
DailyMed Link:	NARCAN at DailyMed

See drug prices for NARCAN

Recent Clinical Trials for NARCAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of New Mexico	PHASE3
Johns Hopkins University	Phase 3
Cure Addiction Now	Phase 3

See all NARCAN clinical trials

Pharmacology for NARCAN

Drug Class	Opioid Antagonist
Mechanism of Action	Opioid Antagonists

Paragraph IV (Patent) Challenges for NARCAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NARCAN	Nasal Spray	naloxone hydrochloride	2 mg/spray	208411	1	2017-12-28
NARCAN	Nasal Spray	naloxone hydrochloride	4 mg/spray	208411	1	2016-07-15

US Patents and Regulatory Information for NARCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Adapt	NARCAN	naloxone hydrochloride	INJECTABLE;INJECTION	016636-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Emergent	NARCAN	naloxone hydrochloride	SPRAY, METERED;NASAL	208411-002	Jan 24, 2017		DISCN	Yes	No
Bristol Myers Squibb	NARCAN	naloxone hydrochloride	INJECTABLE;INJECTION	071083-001	Jul 28, 1988		DISCN	No	No
Emergent	NARCAN	naloxone hydrochloride	SPRAY, METERED;NASAL	208411-001	Nov 18, 2015		OTC	Yes	Yes
Adapt	NARCAN	naloxone hydrochloride	INJECTABLE;INJECTION	016636-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

International Patents for NARCAN

See the table below for patents covering NARCAN around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	272294
Japan	2017508800	経鼻薬物製品およびその使用方法
Canada	2950687	PRODUITS DE MEDICAMENT ADMINISTRE PAR VOIE NASALE ET METHODES D'UTILISATION ASSOCIEES (NASAL DRUG PRODUCTS AND METHODS OF THEIR USE)
United Kingdom	201616616
Singapore	11201607281P	NASAL DRUG PRODUCTS AND METHODS OF THEIR USE

Supplementary Protection Certificates for NARCAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE

Market Dynamics and Financial Trajectory for NARCAN (Naloxone)

Last updated: January 6, 2026

---

Executive Summary

NARCAN (naloxone) has emerged as a critical pharmaceutical intervention in the global opioid crisis, driven by escalating overdose deaths and stringent regulatory responses. Its market is characterized by rapid growth, a shifting regulatory landscape, and evolving manufacturing and distribution channels. This report delineates the current market size, growth trajectories, competitive landscape, regulatory influences, and forecasts NARCAN’s financial prospects over the next five years. Integral to strategic planning are the dynamics of public health policies, pharmaceutical innovation, and distinct regional factors shaping supply and demand.

---

What Is NARCAN?

NARCAN is a nasal spray formulation of naloxone, an opioid antagonist used to reverse acute opioid overdoses. Its ease of administration and critical life-saving role have driven widespread adoption globally. Approved by the FDA in 2015, NARCAN depicts a quintessential over-the-counter (OTC) and prescription drug intersect with broad public health initiatives.

---

Global Market Size and Trends

Current Market Valuation and Growth Rates

Year	Market Size (USD billion)	CAGR (2018-2022)	Key Drivers
2018	$500 million	—	Rising opioid overdose deaths
2022	$1.2 billion	~23%	Policy shifts, increased awareness, OTC availability

Source: IQVIA, 2022.

The rapid compound annual growth rate underscores the urgent demand and market expansion in response to public health needs.

Global Regions and Distribution

Region	Market Share (2022)	Key Factors
North America	70%	Regulatory approvals, high overdose mortality, insurance coverage
Europe	15%	Growing legislation, public health initiatives
Asia-Pacific	10%	Emerging awareness, nascent markets
Rest of World	5%	Limited access, regulatory hurdles

NORTH AMERICA dominates, driven by federal and state overdose mitigation policies.

---

Market Drivers and Constraints

Key Drivers

• Escalating Opioid Crisis: The CDC reported over 100,000 overdose deaths annually in the U.S. since 2020 [1].
• Regulatory Approvals & Policy Mandates: Increasingly, governments mandate or incentivize OTC access to naloxone.
• Public Health Campaigns: North American initiatives promote widespread naloxone availability.
• Innovation & Formulation: Development of easy-to-administer products (e.g., nasal sprays) reduces barriers.

Constraints

• Pricing & Reimbursement Challenges: High costs and limited insurance coverage in some regions impair accessibility.
• Supply Chain Disruptions: Manufacturing constraints and global logistic challenges impact distribution.
• Regulatory Hurdles: Variability in approvals across regions slows market expansion.

---

Competitive Landscape

Company	Product Portfolio	Market Share (2022)	Notable Initiatives
Adapt Pharma (Eli Lilly)	NARCAN nasal spray	~60%	Launch of OTC formulations, global expansion
Mylan	Generic naloxone products	~20%	Cost-effective alternatives
Emergent BioSolutions	Injectable naloxone	~10%	Focus on emergency kits
Others	Diverse formulations	~10%	Niche and emerging products

Adapt Pharma (acquired by Eli Lilly in 2019 for $8 billion) dominates owing to early market entry and successful marketing campaigns.

---

Financial Trajectory and Forecasts

Revenue Projections (2023-2028)

Year	Predicted Market Size (USD billion)	CAGR	Key Assumptions
2023	$1.45 billion	20.8%	Continued policy support, expansion in OTC segment
2024	$1.75 billion	20%	Increased distribution, new regional approvals
2025	$2.12 billion	21%	Heightened overdose rates, innovative formulations
2026	$2.56 billion	21%	Regulatory easing in emerging markets
2027	$3.09 billion	21%	Strategic partnerships, lower cost generics
2028	$3.73 billion	21%	Global market penetration

Forecasting Models and Assumptions

• Market Adoption: Expected rapid uptake driven by OTC availability.
• Pricing Trends: Slight declines in device prices but growth in volume.
• Regulatory Environment: Favorable, with additional countries legalizing OTC naloxone.
• Public Health Policies: Increased emphasis on overdose prevention programs.

---

Regional Regulatory and Policy Impacts

Region	Key Policies & Regulations	Impact
North America	FDA approval for OTC in 2019; state mandates for schools and pharmacies	Accelerates market growth
Europe	Varied approval; some countries allowing OTC sales	Moderate growth, pending regulatory alignment
Asia-Pacific	Emerging markets with policy hurdles; increasing awareness	Growth potential, current low penetration
Latin America	Limited policies; high awareness gaps	Niche markets, policy advocacy needed

---

Comparative Analysis: NARCAN vs. Alternatives

Aspect	NARCAN (Brand-Name)	Generic Naloxone Products	Injectable Naloxone
Formulation	Nasal spray (easy-to-use)	Varies, injectables	Injectable
Regulation	OTC and Rx permitted	Often Rx-only	Rx-only
Cost per dose	~$130 (dealer price)	$20-$50	$15-$30
Accessibility	High, OTC availability	Moderate, Rx requirement	Emergency kits, clinics
User-Friendliness	Very high	Moderate	Low

NARCAN’s ease of use and regulatory support position it favorably against alternatives, although price remains a challenge.

---

Key Market Trends and Innovations

• OTC Expansion: Post-2019 FDA approval, OTC sales surged, and policy shifts in US states increased access.
• Pediatric Formulations: Growing focus to include formulations suitable for children.
• Combination Products: Development of combo kits with other overdose response tools.
• Digital & Educational Campaigns: Increased efforts to educate at-risk populations.

---

Conclusion: Strategic Outlook and Investment Implications

The NARCAN market is poised for substantial expansion, driven by persistent opioid overdose epidemics, supportive regulatory environments, and ongoing innovation. Pharmaceutical firms investing in manufacturing capacity, global regulatory navigation, and strategic collaborations are well-positioned to capitalize on this trajectory. However, pricing strategies, reimbursement models, and supply chain resilience are critical risk factors—mitigating these through strategic partnerships and cost optimization will be pivotal.

---

Key Takeaways

• Market Growth: Expected CAGR of approximately 21% from 2023-2028, reaching over $3.7 billion globally.
• Regulatory Impact: FDA OTC approval and regional policy shifts accelerate access and adoption.
• Competitive Position: Adapt/Eli Lilly leads, with generics and injectables maintaining niche segments.
• Innovation and Accessibility: Focus on user-friendly formulations and affordability will shape future adoption.
• Regional Expansion: Significant growth potential exists outside North America, especially in emerging markets.

---

FAQs

1. What factors are primarily driving the growth of NARCAN?
The opioid epidemic, regulatory approvals for OTC distribution, public health initiatives, and innovations in user-friendly formulations are key drivers.

2. How do pricing and reimbursement impact NARCAN’s market expansion?
High costs and limited insurance reimbursement pose barriers, especially in low-resource settings, constraining access despite demand.

3. What regulatory hurdles exist for NARCAN in emerging markets?
Variability in regulatory frameworks, limited awareness, and healthcare infrastructure deficiencies slow approvals and distribution.

4. How does NARCAN compare with generic naloxone products?
While generics are cost-effective, NARCAN’s ease of administration and brand recognition favor its widespread adoption.

5. What future innovations could influence NARCAN’s market trajectory?
Development of pediatric formulations, combination overdose kits, and digital educational platforms could enhance accessibility and usage.

---

References

[1] Centers for Disease Control and Prevention (CDC). "Opioid Overdose Data." 2022.